Clinical trials: Differentiation
PolG, Primary Mitochondrial Myopathy
Prospective Natural History Study of POLG Disease
The PIONEER study is a prospective, natural history study dedicated to characterizing the clinical progression of POLG-related disorders.
- Trial name
- PIONEER (NCT07775872)
- Where
- 21 sites in United States, Australia and 7 more
- Volunteers
- 300 people
- Sponsor
- The POLG Foundation
Leukemia
S0301 Cyclosporine, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy, such as cyclosporine, daunorubicin, and cytarabine, use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00066794
- Testing
- filgrastim, sargramostim, cyclosporine
- Where
- 97 sites in United States
- Volunteers
- 69 people
- Sponsor
- SWOG Cancer Research Network
Advanced Synovial Sarcoma
FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors
This Phase 1, multicenter, open-label, dose escalation and expansion study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of FHD-609 given…
- Trial name
- NCT04965753
- Testing
- FHD-609
- Where
- 12 sites in United States, France and 2 more
- Volunteers
- 55 people
- Sponsor
- Foghorn Therapeutics Inc.
Procalcitonin, Pneumonia
Procalcitonin Test for Differentiation of the Cause of Pneumonia
The purpose of this study is to evaluate the usefulness of procalcitonin test for differentiation of the cause of pneumonia in patients with cancer.
- Conditions
- Procalcitonin, Pneumonia, Cancer
- Trial name
- NCT03350802
- Testing
- procalcitonin test
- Where
- South Korea
- Volunteers
- 649 people
- Sponsor
- National Cancer Center, Korea
Soft Tissue Sarcoma, Osteosarcoma
Huntsman Biopsy Study
Bone and soft tissue sarcomas are currently classified based upon light microscopy supplemented by immunohistochemistry, but within many if not all of these tumor histologic types, considerable heterogeneity exists not only in…
- Trial name
- NCT00615329
- Where
- United States
- Volunteers
- 142 people
- Sponsor
- State University of New York - Upstate Medical University
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
This phase 2 trial studies how well ixazomib(MLN9708) works in treating study participants with relapsed or refractory acute myeloid leukemia.
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b)
- Trial name
- NCT02030405
- Testing
- Ixazomib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Steven E. Coutre
Leukemia
Arsenic Trioxide in Treating Patients With Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have acute…
- Trial name
- NCT00005795
- Testing
- arsenic trioxide
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Northwestern University
Hepatocellular Carcinoma
Preoperative Prediction of Microvascular Invasion in Hepatocellular Carcinoma
Microvascular invasion (MVI) has been well demonstrated as an unfavorable prognostic factor for hepatocellular carcinoma (HCC), and patients with MVI have a high risk of tumor recurrence after curative hepatectomy.
- Trial name
- NCT03198975
- Testing
- Magnetic resonance image
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Ming Kuang
Type 1 Diabetes Mellitus
Safety, Tolerability, and Efficacy of Immunomodulation With A Monoclonal Antibody Against CD40L in Combination With Transplanted Islet Cells in Adults With Brittle Type 1 Diabetes Mellitus (T1D)
Tegoprubart (AT-1501) is a monoclonal antibody. Antibodies are Y-shaped proteins that are produced naturally by the subject's immune system to attack and fight foreign substances that cause illness.
- Trial name
- Tegoprubart (NCT06305286)
- Testing
- Islet transplantation with Tegoprubart (AT-1501) immunosupression-based therapy
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- University of Chicago
NSCLC
Surufatinib Combined With Tislelizumab in Advanced Lung Cancer With Neuroendocrine Differentiation
Currently, there are no standard treatment and relevant exploration for NSCLC patients with NED. The study aims to explore the efficacy and safety of surufatinib combined with tislelizumab in the treatment of NSCLC with NED, in…
- Trial name
- NCT06414915
- Testing
- Surufatinib, Tislelizumab
- Volunteers
- 29 people
- Sponsor
- National Cancer Center, China
Thyroid Cancer, Metastases
Comparison of Dosimetry After rhTSH or Withdrawal of Thyroid Hormone in Metastatic or Locally Advanced Thyroid Cancer
Metastases of thyroid cancer with iodine uptake are treated with repeated activity of I-131 administered after thyroid hormone withdrawal.
- Trial name
- DOSIMETA (NCT01403324)
- Testing
- TSH stimulation
- Where
- France
- Volunteers
- 4 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
HIV
DSD Models at Malawi Sentinel Sites (SENTINEL 2-Malawi)
To achieve global goals for the treatment of HIV, many countries are piloting and scaling up differentiated service delivery models (DSD).
- Trial name
- SENTINEL2MW (NCT05901727)
- Testing
- No intervention
- Where
- Malawi
- Volunteers
- 15,520 people
- Sponsor
- Boston University
Adult Acute Erythroid Leukemia (M6), Adult Acute Megakaryoblastic Leukemia (M7)
Vorinostat in Treating Patients With Acute Myeloid Leukemia
Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for their growth. Giving the drug in different ways may kill more cancer cells.
- Conditions
- Adult Acute Erythroid Leukemia (M6), Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a)
- Trial name
- NCT00305773
- Testing
- vorinostat
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Neuroendocrine Carcinoma of the Lung and Thymus
3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial
This was a multicenter, randomized, phase II study evaluating Everolimus or Pasireotide LAR alone or in combination in adult patients with advanced (unresectable or metastatic) neuroendocrine carcinoma of the lung and thymus
- Trial name
- LUNA (NCT01563354)
- Testing
- Pasireotide LAR, Everolimus, Pasireotide LAR and Everolimus Combination
- Where
- 36 sites in Denmark, France and 7 more
- Volunteers
- 124 people
- Sponsor
- Novartis Pharmaceuticals
Thyroid Cancer
A Pilot Clinical Trial for Poorly Differentiated Thyroid Cancer - Correlation to Retinoid and Peroxisome-proliferator-activated Receptor (PPARy) Expression
This study plans to learn more about a drug called bexarotene for the treatment of advanced thyroid cancer. Subjects are asked to be in this study because they have thyroid cancer that will not respond to radioactive iodine…
- Trial name
- NCT00718770
- Testing
- Bexarotene
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Colorado, Denver
Differentiated Thyroid Gland Carcinoma, Follicular Variant Thyroid Gland Papillary Carcinoma
Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer
This phase II trial studies how well cabozantinib, nivolumab, and ipilimumab work in treating patients with differentiated thyroid cancer that does not respond to radioactive iodine and that worsened after treatment with a drug…
- Conditions
- Differentiated Thyroid Gland Carcinoma, Follicular Variant Thyroid Gland Papillary Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Refractory Differentiated Thyroid Gland Carcinoma
- Trial name
- NCT03914300
- Testing
- Biospecimen Collection, Cabozantinib S-malate, Computed Tomography
- Where
- 33 sites in United States
- Volunteers
- 11 people
- Sponsor
- National Cancer Institute (NCI)
Acne Vulgaris, Gingivitis and Periodontal Diseases
Retinoic Acid Therapy and Regulation of Salivary and Serum IL-1β, IL-8 and MCP-1 Levels
This prospective cohort study analysed the effects of systemic retinoic acid use on periodontal status, salivary flow rate (SFR), and salivary and serum levels of interleukin (IL)-1β, IL-8 and monocyte chemoattractant protein…
- Conditions
- Acne Vulgaris, Gingivitis and Periodontal Diseases, Saliva Collection, Inflammation Biomarkers
- Trial name
- NCT06879795
- Where
- Turkey (Türkiye)
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Medipol University
HIV Infections
Client and Provider Preferences for HIV Care
This study will investigate preferences for HIV care among participants enrolled in the "Study to evaluate the feasibility of Community-based Test and Treat strategies among men who have sex with men and transgender women to…
- Trial name
- NCT03216798
- Testing
- questionnaires survey
- Where
- Thailand
- Volunteers
- 370 people
- Sponsor
- Thai Red Cross AIDS Research Centre
Healthy Volunteers
Exercise Induced Changes in Fat Metabolism
If eligible to participate in the research study after completing the physical screening procedures, participants will be asked to return to the Substrate Metabolism Laboratory on another occasion after a short fast (no food or…
- Trial name
- BC (NCT02581306)
- Testing
- Exercise session
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Advanced Malignancies
A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody Injection (IBI188) in Patients With Advanced Malignant Tumors and Lymphomas
This is an open-label, dose escalation, Phase I study to evaluate the safety, tolerability, pharmacokinetics and efficacy in patients with advanced malignancies.
- Trial name
- NCT03763149
- Testing
- IBI188
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.